Annovis, Anavex, And Cassava Sciences: Trying To Box Oneself Out Of The Alzheimer's Box [Seeking Alpha]
Cassava Sciences, Inc. (SAVA)
Last cassava sciences, inc. earnings: 8/12 08:30 am
Check Earnings Report
Company Research
Source: Seeking Alpha
Many current drug candidates for Alzheimer's disease work too far upstream in the disease process and do not directly scavenge oxidants, so they may only slow down mild Alzheimer's disease. Anavex's blarcamesine unlike Cassava Sciences' simufilam and Annovis's butanentap may nearly stabilize mild cognitive impairment and mild Alzheimer's disease for three years because it probably acts as a direct antioxidant. For this reason, investment in Anavex is probably still warranted. Recent results for Annovis's ( ANVS ) buntanetap appear to add to the list of treatments that do not help moderate Alzheimer's disease patients. This list includes anti-amyloid antibody drugs such as Leqembi (Eisai and Biogen) and donanemab (Eli Lilly), and sigma-1 receptor agonists such as Recommended For You
Show less
Read more
Impact Snapshot
Event Time:
SAVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SAVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SAVA alerts
High impacting Cassava Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
SAVA
News
- Cassava Sciences, Inc. (NASDAQ: SAVA) had its price target raised by analysts at HC Wainwright from $124.00 to $131.00. They now have a "buy" rating on the stock.MarketBeat
- Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam [Yahoo! Finance]Yahoo! Finance
- Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of SimufilamGlobeNewswire
- Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution [Yahoo! Finance]Yahoo! Finance
- Cassava Sciences Announces Over $125 Million Raised from Warrant DistributionGlobeNewswire
SAVA
Earnings
- 5/10/24 - Beat
SAVA
Analyst Actions
- 3/5/24 - HC Wainwright
SAVA
Sec Filings
- 5/16/24 - Form 4
- 5/13/24 - Form 8-K
- 5/13/24 - Form 4
- SAVA's page on the SEC website